The clinical value of oral robotic surgery in the treatment of oropharyngeal squamous cell carcinoma.
10.3760/cma.j.cn112152-20200731-00698
- Author:
Xing ZHANG
1
;
Zhong Yuan YANG
1
;
An Kui YANG
1
;
Quan ZHANG
1
;
Qiu Li LI
1
;
Shu Wei CHEN
1
;
Jing Tao CHEN
1
;
Ming SONG
1
Author Information
1. Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Publication Type:Journal Article
- Keywords:
Human papilloma virus;
Oropharyngeal squamous cell carcinoma;
Overall survival;
Progression-free survival;
Transoral robotic surgery
- MeSH:
Head and Neck Neoplasms;
Humans;
Oropharyngeal Neoplasms/surgery*;
Papillomavirus Infections/complications*;
Retrospective Studies;
Robotic Surgical Procedures/methods*;
Squamous Cell Carcinoma of Head and Neck/surgery*
- From:
Chinese Journal of Oncology
2022;44(6):570-576
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the therapeutic effects of transoral robotic surgery (TORS) and traditional surgical modes in oropharyngeal squamous cell carcinoma (OPSCC). Methods: The clinicopathological data of patients with oropharyngeal squamous cell carcinoma treated at Sun Yat-sen University Cancer Center from 2010 to 2018 were retrospectively analyzed. 135 cases were treated with traditional surgery (non-TORS group), while 52 cases were treated with TORS (TORS group). The prognosis of the two groups of patients were analyzed by Kaplan-Meier method and Log rank test, the influencing factors were analyzed by Cox regression model. Results: The 2-year overall survival (OS, 94.2%) and 2-year progression-free survival (PFS, 93.8%) of patients in the TORS group were better than those in the non-TORS group (71.4% and 71.4%, respectively, P<0.05). The 2-year OS (93.3%) and 2-year PFS (92.8%) of TORS group patients in T1-2 stage were better than those of non-TORS group (73.1% and 72.8%, respectively, P<0.05). The 2-year OS (95.8%) and 2-year PFS (95.2%) of patients with stage Ⅰ to Ⅱ in the TORS group were not significantly different from those in the non-TORS group (84.1% and 83.9%, respectively, P>0.05). The 2-year OS (92.9%) and 2-year PFS rate (92.7%) of patients with stage Ⅲ to Ⅳ in the TORS group were better than those in the non-TORS group (64.7% and 63.9%, respectively, P<0.05). The 2-year OS (94.4%) of HPV-positive patients in the TORS group was not significantly different from that in the non-TORS group (83.3%, P=0.222). The 2-year OS of HPV-negative patients in the TORS group (94.1%) was significantly different from that in the non-TORS group (43.7%, P<0.001). HPV status was an independent prognostic factor (P=0.008). Conclusions: TORS has a better prognosis in the treatment of oropharyngeal squamous cell carcinoma compared with the traditional treatment methods. The patients with T1-T2 can achieve better survival benefits after TORS treatment. The HPV-positive OPSCC patients has a better prognosis than that of HPV-negative OPSCC patients, and regardless of HPV status, OPSCC patients in the TORS group could obtain a better survival prognosis.
